NCT01280825 The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
| NCT ID | NCT01280825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Patients Undergoing Routine Health Care |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2011-01-14 |
| Primary Completion | 2027-11-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2011-01-14 with a primary completion date of 2027-11-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.
Eligibility Criteria
Inclusion Criteria: * Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial * Life expectancy of at least 3 years * Must be 18 years or older * Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years * Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to: * Patients requiring specialized cardiology care * Patients with inflammatory bowel diseases * Patients with systemic autoimmune or inflammatory diseases * Patients requiring long-term oral anticoagulation * Patients with hepatitis C * Patients with non-metastatic cancer Exclusion Criteria: * Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years. * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Inability to understand and give informed consent to participate.
Contact & Investigator
Peter H O'Donnell, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT01280825 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patients Undergoing Routine Health Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01280825 currently recruiting?
Yes, NCT01280825 is actively recruiting participants. Contact the research team at cpt1200@uchicago.edu for enrollment information.
Where is the NCT01280825 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT01280825 clinical trial?
NCT01280825 is sponsored by University of Chicago. The principal investigator is Peter H O'Donnell, MD at University of Chicago. The trial plans to enroll 1,200 participants.